Biotech Watch: The EU’s CHMP backed Merck’s KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin) for perioperative treatment of resectable muscle-invasive bladder cancer, with a final European Commission decision expected in Q4 2026—covering EU states plus Liechtenstein, Iceland and Norway. Biotech Watch: Zealand Pharma also won a positive CHMP opinion for Zeydovio (glepaglutide) to treat short bowel syndrome, touting major reductions in weekly parenteral support and some patients weaning off entirely. Space & Research: CSA and Starlab are building a pathway for microgravity experiments from Swiss ground testing and parabolic flights to the ISS, with plans to extend access to Starlab’s future commercial station. Digital Economy: Google has started removing shopping product carousels across the EEA (EU plus Norway, Iceland and Liechtenstein) to comply with the Digital Markets Act, hitting retailer visibility hard. Finance & Infrastructure: Sygnum’s regulated push for tokenized real-world assets continues as it expands its digital-asset banking footprint, including MiCAR licensing in Liechtenstein. Cross-Border Tech Policy: EU Commission President Ursula von der Leyen floated Canada as the bloc’s first “associate member,” with talks also touching tech, AI, quantum, cybersecurity and research cooperation. Local Business: KPMG appointed Timo Knak as Head of Advisory in Switzerland, adding to its leadership team that also governs a Liechtenstein office from Switzerland.